MedTrace Logo

The Effect of Growth Factor on Implant Osseointegration

NCT04879446 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-05-11

No results posted yet for this study

Summary

In this study, concentrated growth factor obtained by centrifuging the patient's own blood and advanced platelet-rich fibrin liquids were applied to the implant cavity and surface. Thus, it was aimed to ensure that the osseointegration process would start earlier by ensuring a faster arrival of growth factor and healing mediators in the region, and thus, the time waited for the osseointegration process and the loading of the superstructure would be shortened.

In this split-mouth study, a total of 32 patients including two separate study groups in different patients and a control group were included. While the CGF liquid was applied to the implant cavities and surfaces prepared in the study group of 16 patients, A-PRF liquid was applied to the study group of the other 16 patients. Conventional implant application was performed in the control groups of both groups. The torque values during the implantation were also recorded, and Resonance Frequency measurements were performed immediately after implantation with the Penguin RFA device and at postoperative weeks 2, 4, 6 and 12.

Conditions

  • Bone Loss, Alveolar
  • Resorption, Bone
  • Osseointegration Failure of Dental Implant

Interventions

PROCEDURE

Concentrated growth factor(CGF)

Concentrated growth factor(CGF) liquid applied to the implant cavity and implant surface.

PROCEDURE

Advanced platelet rich fibrin (A-PRF)

Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity and implant surface.

PROCEDURE

Control side of concentrated growth factor study group

Traditional implant methods applied.

PROCEDURE

Control side of advanced platelet rich fibrin study group

Traditional implant methods applied.

Sponsors & Collaborators

  • Mustafa Kemal University

    collaborator OTHER

  • Uğur Can ÜNLÜGENÇ

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
38 Years
Max Age
58 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-10
Primary Completion
2020-12-21
Completion
2021-03-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04879446 on ClinicalTrials.gov